Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Kidney Transplant I: Introduction01:28

Kidney Transplant I: Introduction

30
A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
30
Kidney Transplant II: Surgical Procedure01:26

Kidney Transplant II: Surgical Procedure

41
Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living...
41
Kidney Transplant III: Nursing Management01:16

Kidney Transplant III: Nursing Management

49
Postoperative Nursing Management for Kidney Transplant PatientsPostoperative nursing management care includes monitoring the surgical site, encouraging early movement, and promoting lung health through breathing exercises. Nurses also administer prescribed medications like H2-blockers, such as famotidine, or proton pump inhibitors, like omeprazole, to help prevent gastrointestinal ulcers and bleeding. Fungal infections in the mouth and bladder can result from immunosuppressive and antibiotic...
49
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

69.4K
Overview
69.4K
Acute Kidney Injury II: Pathophysiology01:29

Acute Kidney Injury II: Pathophysiology

40
Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...
40
Tissue Transplantation01:24

Tissue Transplantation

442
Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
442

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

International Society of Nephrology's 0by25 initiative for acute kidney injury (zero preventable deaths by 2025): a human rights case for nephrology.

Lancet (London, England)·2015
Same author

Rare diseases and effective treatments: are we delivering?

Lancet (London, England)·2015
Same author

Direct reprogramming of human bone marrow stromal cells into functional renal cells using cell-free extracts.

Stem cell reports·2015
Same author

Renal progenitors derived from human iPSCs engraft and restore function in a mouse model of acute kidney injury.

Scientific reports·2015
Same author

Need for chronic kidney disease prevention programs in disadvantaged populations.

Clinical nephrology·2015
Same author

Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial.

The lancet. Diabetes & endocrinology·2015
Same journal

Hepatic Congestion-linked Intrahepatic Biliary Strictures After Living Donor Liver Transplantation.

Transplantation·2026
Same journal

Filtered or Fried? Rethinking Intraoperative Cell Salvage in Liver Transplantation.

Transplantation·2026
Same journal

Simultaneous Liver-kidney Versus Liver Transplantation Categorized by Pretransplant eGFR: Impact of the 2017 OPTN Policy.

Transplantation·2026
Same journal

Preformed Anti-DQ Alpha Donor-specific Antibodies and the Risk of Antibody-mediated Rejection After Kidney Transplantation.

Transplantation·2026
Same journal

People in Transplantation: Professor Nadey Hakim, MD, PhD, FRCS, FRCSGlas (Hon), FACS, President-Elect of The Transplantation Society.

Transplantation·2026
Same journal

IL-1 Receptor Blockade Modulates Inflammation During Sequential Perfusion in Ex Vivo Porcine Kidneys.

Transplantation·2026
See all related articles

Related Experiment Video

Updated: Aug 6, 2025

Murine Kidney Transplant Technique
08:58

Murine Kidney Transplant Technique

Published on: October 20, 2015

16.3K

TMA in Kidney Transplantation.

Zahra Imanifard1, Lucia Liguori, Giuseppe Remuzzi

  • 1Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Clinical Research Center for Rare Diseases Aldo e Cele Daccò, Ranica, Italy.

Transplantation
|March 22, 2023
PubMed
Summary
This summary is machine-generated.

Posttransplant thrombotic microangiopathy (PT-TMA) is a serious kidney transplant complication. Targeted complement inhibition shows promise for treating both de novo and recurrent PT-TMA, improving outcomes.

More Related Videos

A Modified Surgical Technique for Kidney Transplantation in Mice
10:38

A Modified Surgical Technique for Kidney Transplantation in Mice

Published on: July 22, 2022

6.0K
Mouse Kidney Transplantation: Models of Allograft Rejection
16:15

Mouse Kidney Transplantation: Models of Allograft Rejection

Published on: October 11, 2014

20.8K

Related Experiment Videos

Last Updated: Aug 6, 2025

Murine Kidney Transplant Technique
08:58

Murine Kidney Transplant Technique

Published on: October 20, 2015

16.3K
A Modified Surgical Technique for Kidney Transplantation in Mice
10:38

A Modified Surgical Technique for Kidney Transplantation in Mice

Published on: July 22, 2022

6.0K
Mouse Kidney Transplantation: Models of Allograft Rejection
16:15

Mouse Kidney Transplantation: Models of Allograft Rejection

Published on: October 11, 2014

20.8K

Area of Science:

  • Nephrology
  • Transplantation immunology
  • Complement system biology

Background:

  • Thrombotic microangiopathy (TMA) is a rare but severe complication following kidney transplantation, often leading to graft loss.
  • Posttransplant TMA (PT-TMA) can arise de novo or recur, influenced by factors like immunosuppressants, rejection, infections, and ischemia/reperfusion injury.
  • Recurrent TMA in kidney grafts is linked to atypical hemolytic uremic syndrome (aHUS), with genetic complement pathway abnormalities or autoantibodies against complement factor H (CFH) being key factors.

Purpose of the Study:

  • To review the mechanisms and treatment strategies for de novo and recurrent posttransplant thrombotic microangiopathy (PT-TMA).
  • To highlight the role of complement dysregulation in PT-TMA pathogenesis.
  • To evaluate the efficacy of targeted complement inhibition in managing PT-TMA.

Main Methods:

  • Review of existing literature on PT-TMA, focusing on causes, recurrence factors, and treatment outcomes.
  • Analysis of genetic and acquired abnormalities in the complement system associated with aHUS and PT-TMA.
  • Evaluation of therapeutic interventions, including plasma exchange and complement inhibitors.

Main Results:

  • De novo PT-TMA can be triggered by various factors, while recurrent TMA is often associated with underlying complement abnormalities.
  • Genetic defects in complement regulators (CFH, MCP, CFI) or components (C3, CFB), and anti-CFH autoantibodies are implicated in aHUS recurrence.
  • Plasma exchange addresses hematologic issues but not graft function; targeted complement inhibition is effective for recurrent TMA and potentially beneficial for de novo PT-TMA.

Conclusions:

  • Understanding the specific complement abnormality is crucial for tailoring PT-TMA treatment.
  • Targeted complement inhibition represents a promising therapeutic avenue for PT-TMA, requiring further research to optimize patient selection and application.
  • Effective management of PT-TMA necessitates a personalized approach based on the underlying cause, whether de novo or recurrent, and the specific complement pathway involvement.